| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2025-01-20 |
| タイトル |
|
|
タイトル |
Outcomes and Prognostic Analysis of Surgical Resection for Oligometastasis from Hepatocellular Carcinoma |
|
言語 |
en |
| 作成者 |
OSHITA, KO
KOBAYASHI, TSUYOSHI
TADOKORO, TAKESHI
NAMBA, YOSUKE
FUKUHARA, SOTARO
MATSUBARA, KEISO
TAKEI, DAISUKE
HONMYO, NARUHIKO
KURODA, SHINTARO
KAWAOKA, TOMOKAZU
AIKATA, HIROSHI
OHDAN, HIDEKI
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is not the published version. Please cite only the published version. |
| 権利情報 |
|
|
言語 |
ja |
|
権利情報 |
この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。 |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Hepatocellular carcinoma |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
oligometastasis |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
surgical resection |
| 内容記述 |
|
|
内容記述 |
Background/Aim: This study aimed to evaluate the outcomes of patients who underwent resection for oligometastasis from hepatocellular carcinoma (HCC) and identify the prognostic factors associated with poor survival. Patients and Methods: Patients who underwent resection for oligometastasis from HCC between January 2000 and April 2021 were retrospectively investigated. Oligometastasis was defined as 1-5 single organ metastases that were detected preoperatively in this study. Clinical characteristics and treatment outcomes were analyzed, and independent risk factors for poor prognosis were identified using cox proportional hazards model. Results: A total of 33 patients were included in this study. Eleven oligometastases were located in the intraabdominal lymph node, 8 in the adrenal gland, 5 in the lung, 4 in the peritoneum, 3 in the pleura, and 1 each in the supraclavicular lymph node and abdominal wall. No re-operation or operative death occurred in this study. The median OS was 44.6 months (range=5.1-150.6 months), and the median survival after primary HCC diagnosis was 116.5 months (range=7.1-253.6 months). The median cumulative incidence of recurrent HCC was 7.2 months (range=0.3-94.7 months). The multivariate analysis showed that an alpha-fetoprotein level ≥20 ng/ml and multiple primary HCC tumors were independent poor prognostic factors. Conclusion: Clinical characteristics and treatment outcomes of patients who underwent resection for oligometastasis from HCC were demonstrated. A high alpha-fetoprotein level and multiple primary HCC tumors were independent poor prognostic factors. Surgical resection can be one of the treatment options for oligometastasis from HCC. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
International Institute of Anticancer Research |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.21873/anticanres.16720 |
| 助成情報 |
|
|
|
助成機関名 |
日本医療研究開発機構 |
|
|
言語 |
ja |
|
|
研究課題番号 |
JP22fk0210108 |
|
|
研究課題名 |
分化制御NK細胞を用いた免疫療法による新規肝炎/肝癌治療の開発研究 |
|
|
言語 |
ja |
| 助成情報 |
|
|
|
助成機関名 |
Japan Agency for Medical Research and Development (AMED) |
|
|
言語 |
en |
|
|
研究課題名 |
分化制御NK細胞を用いた免疫療法による新規肝炎/肝癌治療の開発研究 |
|
|
言語 |
ja |
| 開始ページ |
|
|
開始ページ |
5189 |
| 書誌情報 |
en : Anticancer Research
巻 43,
号 11,
p. 5189-5196,
発行日 2023-11-01
|
| 旧ID |
56130 |
ActicancerRes_43_5189.pdf (658.8 KB)
